155 related articles for article (PubMed ID: 22175142)
21. CINCA syndrome in an infant presenting with hydrocephalus.
Turel O; Goknar N; Uzuner S; Kasapcopur O; Cuisset L
Int J Rheum Dis; 2014 Mar; 17(3):346-8. PubMed ID: 24618115
[No Abstract] [Full Text] [Related]
22. Neonatal treatment of CINCA syndrome.
Paccaud Y; Berthet G; Von Scheven-Gête A; Vaudaux B; Mivelaz Y; Hofer M; Roth-Kleiner M
Pediatr Rheumatol Online J; 2014; 12():52. PubMed ID: 25584041
[TBL] [Abstract][Full Text] [Related]
23. Cryopyrin-associated periodic syndrome.
Posch C; Kaulfersch W; Rappersberger K
Pediatr Dermatol; 2014; 31(2):228-31. PubMed ID: 22891689
[TBL] [Abstract][Full Text] [Related]
24. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.
Goldbach-Mansky R; Kastner DL
J Allergy Clin Immunol; 2009 Dec; 124(6):1141-9; quiz 1150-1. PubMed ID: 20004775
[TBL] [Abstract][Full Text] [Related]
25. [Muckle-Wells syndrome caused by a new cryopyrin mutation: effective treatment with interleukin-1 antagonist].
Rameev VV; Kozlovskaia LV; Bogdanova MV
Ter Arkh; 2012; 84(6):53-9. PubMed ID: 22997920
[TBL] [Abstract][Full Text] [Related]
26. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
Koné-Paut I; Galeotti C
Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
[TBL] [Abstract][Full Text] [Related]
27. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
Cohen SB
Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
[TBL] [Abstract][Full Text] [Related]
28. [Cryopyrin-associated periodic syndromes].
Quartier P; Rodrigues F; Georgin-Lavialle S
Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
[TBL] [Abstract][Full Text] [Related]
29. Muckle-Wells syndrome: manifestations and diagnosis in four generations of a Portuguese family.
Azevedo SRL; Peixoto DFM
World J Pediatr; 2020 Oct; 16(5):541-542. PubMed ID: 32246440
[No Abstract] [Full Text] [Related]
30. The trials of anakinra.
Burls A; Jobanputra P
Lancet; 2004 Sep 4-10; 364(9437):827-8. PubMed ID: 15351176
[No Abstract] [Full Text] [Related]
31. [When are "biologics" indicated?].
MMW Fortschr Med; 2006 Apr; 148(17):10. PubMed ID: 16711479
[No Abstract] [Full Text] [Related]
32. [Redefining treatment of rheumatic arthritis with anti-cytokines].
Gabay C; So A
Rev Med Suisse; 2007 Mar; 3(103):715-7. PubMed ID: 17458148
[No Abstract] [Full Text] [Related]
33. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 3. T-cell costimulation blocker].
Kohsaka H
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2979-84. PubMed ID: 22175141
[No Abstract] [Full Text] [Related]
35. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
Lipsker D; Lenormand C
Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
[TBL] [Abstract][Full Text] [Related]
36. TNF-alpha antagonists and other recombinant proteins for the treatment of rheumatoid arthritis.
Brasington R
J Hand Surg Am; 2009 Feb; 34(2):349-50. PubMed ID: 19135810
[No Abstract] [Full Text] [Related]
37. Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA).
Rigante D; Leone A; Marrocco R; Laino ME; Stabile A
Rheumatol Int; 2011 Dec; 31(12):1661-4. PubMed ID: 21240490
[TBL] [Abstract][Full Text] [Related]
38. Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1β and rapid response to anakinra.
Sabroe RA; Stokes CA; Parker LC; Higgins K; Prince LR; Sabroe I
Clin Exp Dermatol; 2013 Dec; 38(8):874-7. PubMed ID: 23889084
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 2. Salazosulfapyridine].
Kawai S
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2910-7. PubMed ID: 22175130
[No Abstract] [Full Text] [Related]
40. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 1. Methotrexate].
Suzuki Y; Chinen N
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2902-9. PubMed ID: 22175129
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
